AU2006327882A1 - Pharmaceutical combination for the treatment of LUTS comprising a PDE5 inhibitor and a muscarinic antagonist - Google Patents
Pharmaceutical combination for the treatment of LUTS comprising a PDE5 inhibitor and a muscarinic antagonist Download PDFInfo
- Publication number
- AU2006327882A1 AU2006327882A1 AU2006327882A AU2006327882A AU2006327882A1 AU 2006327882 A1 AU2006327882 A1 AU 2006327882A1 AU 2006327882 A AU2006327882 A AU 2006327882A AU 2006327882 A AU2006327882 A AU 2006327882A AU 2006327882 A1 AU2006327882 A1 AU 2006327882A1
- Authority
- AU
- Australia
- Prior art keywords
- ethyl
- pharmaceutically acceptable
- pyrimidin
- pyrazolo
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title claims description 33
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title claims description 33
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title claims description 31
- 239000003149 muscarinic antagonist Substances 0.000 title claims description 28
- 238000011282 treatment Methods 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 44
- 238000009472 formulation Methods 0.000 claims description 39
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 18
- 229960004045 tolterodine Drugs 0.000 claims description 17
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 17
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims description 17
- 229960003310 sildenafil Drugs 0.000 claims description 16
- 229960002978 fesoterodine Drugs 0.000 claims description 14
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims description 14
- -1 methylpyrrolidin-2-yl Chemical group 0.000 claims description 13
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims description 12
- 229960005434 oxybutynin Drugs 0.000 claims description 12
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 8
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 7
- YPFZMBHKIVDSNR-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(CCOC)C(CC)=C3N=2)C(OCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 YPFZMBHKIVDSNR-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229960000835 tadalafil Drugs 0.000 claims description 6
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims description 6
- 229960002381 vardenafil Drugs 0.000 claims description 6
- DUXZAXCGJSBGDW-HXUWFJFHSA-N Desfesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-HXUWFJFHSA-N 0.000 claims description 5
- 229960002677 darifenacin Drugs 0.000 claims description 5
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims description 5
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 4
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 claims description 4
- 206010029446 nocturia Diseases 0.000 claims description 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 4
- 229960002646 scopolamine Drugs 0.000 claims description 4
- 229960003855 solifenacin Drugs 0.000 claims description 4
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims description 4
- INLBUQIADGPECI-UHFFFAOYSA-N 5-(5-acetyl-2-butoxypyridin-3-yl)-3-ethyl-2-(1-ethylazetidin-3-yl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCCOC1=NC=C(C(C)=O)C=C1C1=NC2=C(CC)N(C3CN(CC)C3)N=C2C(=O)N1 INLBUQIADGPECI-UHFFFAOYSA-N 0.000 claims description 3
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 206010046494 urge incontinence Diseases 0.000 claims description 3
- 229930003347 Atropine Natural products 0.000 claims description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 2
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 claims description 2
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000396 atropine Drugs 0.000 claims description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 2
- 229960000307 avanafil Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 229960000697 propantheline Drugs 0.000 claims description 2
- 229960003510 propiverine Drugs 0.000 claims description 2
- 229960001491 trospium Drugs 0.000 claims description 2
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims description 2
- 229960000438 udenafil Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 2
- JFZSDNLQDTYVEE-UHFFFAOYSA-N 1,4-dihydropyrazolo[4,3-d]pyrimidin-7-one Chemical compound O=C1N=CNC2=C1NN=C2 JFZSDNLQDTYVEE-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 58
- 239000003826 tablet Substances 0.000 description 23
- 206010020853 Hypertonic bladder Diseases 0.000 description 17
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 17
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 17
- 208000020629 overactive bladder Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 230000027939 micturition Effects 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 13
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 229940126062 Compound A Drugs 0.000 description 10
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 229960002639 sildenafil citrate Drugs 0.000 description 9
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010046543 Urinary incontinence Diseases 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- WAJNANMQOPCIPO-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-7-one Chemical class O=C1N=CN=C2C=NN=C12 WAJNANMQOPCIPO-UHFFFAOYSA-N 0.000 description 7
- TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 6
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical class C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 3
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 229940080313 sodium starch Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 229960003553 tolterodine tartrate Drugs 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- CWQWIJCDFMPYEF-UHFFFAOYSA-N 2-(2-methoxyethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1C=NC(=O)C2=NN(CCOC)C=C21 CWQWIJCDFMPYEF-UHFFFAOYSA-N 0.000 description 2
- WKISNFXGTYNPOO-OAHLLOKOSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(2r)-1-methoxypropan-2-yl]oxypyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(O[C@H](C)COC)C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=C1 WKISNFXGTYNPOO-OAHLLOKOSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- 101150098694 PDE5A gene Proteins 0.000 description 2
- 208000025844 Prostatic disease Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010052901 Terminal dribbling Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YSUBQYRZZFVMTL-YNDGFOBUSA-N (2s,5r,6r)-6-[[(2r)-2-[[3-[(e)-furan-2-ylmethylideneamino]-2-oxoimidazolidine-1-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)N(C1=O)CCN1\N=C\C1=CC=CO1 YSUBQYRZZFVMTL-YNDGFOBUSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- QUUJQFQTLSFCKW-UHFFFAOYSA-N 1-[4-(1,3-benzodioxol-5-ylmethylamino)-6-chloroquinazolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=NC(NCC=2C=C3OCOC3=CC=2)=C(C=C(Cl)C=C2)C2=N1 QUUJQFQTLSFCKW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BRBNVIXMODBSND-UHFFFAOYSA-N 1-methyl-5-[5-(2-morpholin-4-ylacetyl)-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C=3N(C)N=C(CCC)C=3N=2)C(OCCC)=CC=C1C(=O)CN1CCOCC1 BRBNVIXMODBSND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical compound N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 1
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical class C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
- DMZDMJAFXVYQHZ-UHFFFAOYSA-N 1h-imidazo[4,5-g]quinazoline Chemical compound N1=CN=C2C=C(NC=N3)C3=CC2=C1 DMZDMJAFXVYQHZ-UHFFFAOYSA-N 0.000 description 1
- JUFWEMLZQGRGPE-UHFFFAOYSA-N 1h-imidazo[5,1-f][1,2,4]triazin-2-one Chemical class N1C(=O)N=CC2=CN=CN21 JUFWEMLZQGRGPE-UHFFFAOYSA-N 0.000 description 1
- FSKYZRCACCHDGR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-4-one Chemical class C1=CN=C2C(=O)N=CNC2=C1 FSKYZRCACCHDGR-UHFFFAOYSA-N 0.000 description 1
- VTKJONLXRSQSGR-UHFFFAOYSA-N 2,3,6,6a,7,7a-hexahydropyrazino[1,2-b]$b-carboline-1,4-quinone Chemical class C1=CC=CC2NC(CN3C(=O)CNC(=O)C3=C3)C3=C21 VTKJONLXRSQSGR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZEDCOUIRGFQKTH-UHFFFAOYSA-N 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propylindole-6-carboxylic acid Chemical compound CCCC1=C(C(C)=O)C2=CC=C(C(O)=O)C=C2N1CC1=CC=CC=C1Cl ZEDCOUIRGFQKTH-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- SUNRSIDIGUGCSU-UHFFFAOYSA-N 5-(5-acetyl-2-propoxypyridin-3-yl)-3-ethyl-2-(1-propan-2-ylazetidin-3-yl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=NC=C(C(C)=O)C=C1C1=NC2=C(CC)N(C3CN(C3)C(C)C)N=C2C(=O)N1 SUNRSIDIGUGCSU-UHFFFAOYSA-N 0.000 description 1
- NMEFXGPLRHHGTK-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-phenyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2C1=CC=CC=C1 NMEFXGPLRHHGTK-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- QPBXXHOQSFVUKL-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-2-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CC=N1 QPBXXHOQSFVUKL-UHFFFAOYSA-N 0.000 description 1
- YJMYSLFFZJUXOA-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 YJMYSLFFZJUXOA-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- FFCZQVKVWGGQFB-UHFFFAOYSA-N 9h-pyrido[3,4-b]indole-1,4-dione Chemical compound N1C2=CC=CC=C2C2=C1C(=O)N=CC2=O FFCZQVKVWGGQFB-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010069645 Reduced bladder capacity Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940117229 cialis Drugs 0.000 description 1
- DYIUKMSMAJWWAT-NEPJUHHUSA-N cis-2-hexyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]-imidazo[2, 1-b]purin-4-one Chemical compound N([C@@H]1CCC[C@@H]1N12)=C1N(C)C(=O)C1=C2NC(CCCCCC)=N1 DYIUKMSMAJWWAT-NEPJUHHUSA-N 0.000 description 1
- WOXKDUGGOYFFRN-UHFFFAOYSA-N cis-Tadalafil Chemical compound C1=C2OCOC2=CC(C2C3=C(C4=CC=CC=C4N3)CC3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000036724 intravesical pressure Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229940097443 levitra Drugs 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007896 modified release capsule Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LHBOTJAKRHYQRC-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6,7,8-trimethoxyquinazolin-4-amine Chemical compound N1=CN=C2C(OC)=C(OC)C(OC)=CC2=C1NCC1=CC=C(Cl)C=C1 LHBOTJAKRHYQRC-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- CKRORYDHXIRZCH-UHFFFAOYSA-N phosphoric acid;dihydrate Chemical compound O.O.OP(O)(O)=O CKRORYDHXIRZCH-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 208000022472 post-void dribbling Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical group CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- UYLWKSJTHLRFBX-UHFFFAOYSA-N purin-6-one Chemical class O=C1N=CN=C2N=CN=C12 UYLWKSJTHLRFBX-UHFFFAOYSA-N 0.000 description 1
- 125000004547 quinazolin-6-yl group Chemical group N1=CN=CC2=CC(=CC=C12)* 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- JOSMPBVYYKRYLG-OLZOCXBDSA-N sch-51866 Chemical compound N1([C@H]2CCC[C@H]2N=C1N(C(C=1N2)=O)C)C=1N=C2CC1=CC=C(C(F)(F)F)C=C1 JOSMPBVYYKRYLG-OLZOCXBDSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229940095585 testosterone-5-alpha reductase inhibitors for benign prostatic hypertrophy Drugs 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
WO 2007/072169 PCT/IB2006/003683 1 Pharmaceutical combination for the treatment of LUTS This invention relates to the combined use of a PDE5 inhibitor and a muscarinic antagonist in the treatment of lower urinary tract symptoms (LUTS). 5 LUTS comprise three groups of urinary symptoms, which may be defined as storage (irritative), voiding (obstructive) and post-micturition symptoms. Storage symptoms comprise urgency, frequency, nocturia, urgency incontinence and stress incontinence, which can be associated with overactive bladder (OAB) and benign prostatic hyperplasia 10 (BPH). Voiding symptoms comprise hesitancy, poor flow, intermittency, straining and dysuria. Post-micturition symptoms comprise terminal dribbling, post-void dribbling and a sense of incomplete emptying. Over Active Bladder (OAB) is defined as urgency, with or without urge incontinence, 15 usually with frequency and nocturia [Abrams et al., Neurourology and Urodynamics 21:167-178 (2002)]. Prevalence of OAB in men and women is similar, with approximately 16% of the population of the USA suffering from the condition [Stewart et al, Prevalence of Overactive Bladder in the United States: Results from the NOBLE Program; Abstract Presented at the 2 nd International Consultation on Incontinence, July 20 2001, Paris, France]. The terms OAB Wet and OAB Dry describe OAB patients with or without urinary incontinence respectively. Until recently, the cardinal symptom of OAB was believed to be urinary incontinence. However, with the advent of the new terms this is clearly not 25 meaningful for the large number of sufferers who are not incontinent (i.e. OAB Dry patients). Thus, a recent study from Liberman et al ['Health Related Quality of Life Among Adults with Symptoms of Overactive Bladder: Results From A US Community Based Survey'; Urology 57(6), 1044-1050, 2001] examined the impact of all OAB symptoms on the quality of life of a community-based sample of the US population. This 30 study demonstrated that individuals suffering from OAB without any demonstrable loss of urine have an impaired quality of life when compared with controls.
WO 2007/072169 PCT/IB2006/003683 2 BPH is a chronically progressive disease that can lead to complications such as acute urinary retention, recurrent urinary tract infections, bladder stones and renal dysfunction. The prevalence and average severity of LUTS associated with BPH in men increases with age. 5 BPH leads to an increase in prostate volume, creating urethral and bladder outflow obstruction as well as secondary changes in bladder function. The effects of this are manifested by both storage (irritative) and voiding (obstructive) symptoms. 10 Devan et al ['Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats', Pharmacology, Biochemistry and Behaviour, vol 79, No 4, December 2004, pages 691 699] disclose a study to examine whether sildenafil citrate (a PDE5 inhibitor) would reverse the learning impairment induced by scopolamine (a muscarinic receptor 15 antagonist). However, as is clear from the paragraph bridging pages 694 and 695, the two compounds were administered in separate injections, and were not present in the same formulation. WO 99/02161 discloses the use of selective inhibitors of PDE1, PDE4 and PDE5 in the 20 treatment of prostatic diseases. EP 1020190 discloses the use of PDE5 inhibitors in the treatment of BPH and their combination with a-antagonists for this purpose. 25 WO 01/27112 and WO 01/27113 each disclose a series of pyrazolo[4,3-d]pyrimidin-7 ones which are PDE5 inhibitors. The compounds are indicated, amongst other things, in the treatment of BPH, bladder outlet obstruction and incontinence. WO 99/58478 and its priority document EP 0957073 disclose derivatives of 3,3 30 diphenylpropylamines, including fesoterodine [R-(+)-isobutyric acid 2-(3 diisopropylamino- 1-phenylpropyl)-4-hydroxymethylphenyl ester, see page 62 lines 15-16 of WO 99/58478]. The compounds are indicated in the treatment of urinary incontinence, amongst other things.
WO 2007/072169 PCT/IB2006/003683 3 US 2001/0044438 discloses the combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the treatment of LUTS associated with BPH. 5 US 2004/0180958 (and its equivalent WO 2004/054560) discloses the use of alpha-2-delta ligands in the treatment of LUTS, other than urinary incontinence, associated with OAB and/or BPH. Their combined use with PDE5 inhibitors is also disclosed in the treatment of LUTS associated with OAB and/or BPH. 10 WO 89/06644 and its equivalent EP 325571 discloses a group of 3,3 diphenylpropylamines, including tolterodine [(+)-N,N-diisopropyl-3-(2-hydroxy-5 methylphenyl)-3-phenylpropylamine, see Example 22]. The compounds are indicated in the treatment of urinary incontinence. 15 WO 94/11337 discloses a group of 3,3-diphenylpropylamines, including (+)-N,N diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine (see Example 1), which is also formed by metabolism of tolterodine. The compounds are indicated in the treatment of urinary incontinence. 20 The use of muscarinic antagonists in the treatment of overactive bladder is described in a meeting report by Gopalakrishnan et al, 'Directions in urological research and drug therapies', Drug News and Perspectives, vol 9, No 14, November 2001 (2001-11) pages 544-550. 25 US 6,642,274 discloses a method of treating prostate disorders comprising administering various medicaments directly to the mucosal membranes of the lower urinary tract. Seven classes of therapeutic compounds are suggested for use in the method, including phosphodiesterase inhibitors and anticholinergic agents (a term often used interchangeably with the term "muscarinic antagonists"). There is also a suggestion that such compounds 30 can be used alone or in combination in the disclosed method, but there is no explicit mention of a combination of a PDE5 inhibitor and an anticholinergic agent.
WO 2007/072169 PCT/IB2006/003683 4 WO 99/65228 relates to the treatment of testosterone deficiency in men while simultaneously protecting the prostate. The combinations contain a natural or synthetic androgen; and a compound selected from various classes of compound including testosterone 5-alpha reductase inhibitors and phosphodiesterase inhibitors. 5 WO 01/17480 discloses the treatment of urinary disorders in a mammal comprising administering therapeutic compounds directly to the mucosal membranes of the lower urinary tract. Preferred groups of compounds are stated to be autocoids, cytokines, chemotherapeutic agents, alpha-receptor antagonists, prostaglandin dehydrogenase 10 inhibitors, phosphodiesterase inhibitors, anticholinergic and antispasmodic agents. It has now been found that PDE5 inhibitors and muscarinic antagonists are particularly useful when used together in the treatment of LUTS. 15 Thus, in accordance with a first aspect of the present invention there is provided a pharmaceutical formulation comprising: a PDE5 inhibitor; and a muscarinic antagonist. 20 In accordance with a second aspect of the invention, there is provided the use of a PDE5 inhibitor and a muscarinic antagonist in the manufacture of a medicament for the treatment of LUTS. In accordance with a third aspect of the invention, there is provided a method of treatment 25 of LUTS, comprising simultaneous, separate or sequential administration of a PDE5 inhibitor and a muscarinic antagonist to a patient in need of such treatment. In accordance with a fourth aspect of the invention, there are provided pharmaceutical products comprising a PDE5 inhibitor and a muscarinic antagonist as a combined 30 preparation for simultaneous, separate or sequential use in the treatment of LUTS. The various aspects of the invention are referred to together herein as "the combinations of the invention".
WO 2007/072169 PCT/IB2006/003683 5 The lower urinary tract symptoms of greatest interest are urgency, frequency, nocturia and urge incontinence, especially urgency. 5 The combinations of the invention are suitable for treating both men and women, although LUTS associated with BPH will only be found in men. Men suffering from both LUTS and male erectile dysfunction (MED) may also gain relief from MED symptoms through receiving the combinations of the invention. 10 PDE5 inhibitors suitable for use in the invention include, but are not limited to: (i) the PDE5 inhibitors mentioned in International Patent Applications WO 03/000691; WO 02/64590; WO 02/28865; WO 02/28859; WO 02/38563; WO 02/36593; WO 02/28858; WO 02/00657; WO 02/00656; WO 02/10166; WO 15 02/00658; WO 01/94347; WO 01/94345; WO 00/15639 and WO 00/15228; (ii) the PDE5 inhibitors mentioned in US Patents 6,143,746; 6,143,747 and 6,043,252; (iii) the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in EP 0463756; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in EP 0526004; the pyrazolo [4,3 20 d]pyrimidin-7-ones disclosed in WO 93/06104; the isomeric pyrazolo [3,4 d]pyrimidin-4-ones disclosed in WO 93/07149; the quinazolin-4-ones disclosed in WO 93/12095; the pyrido[3,2-d]pyrimidin-4-ones disclosed in WO 94/05661; the purin-6-ones disclosed in WO 94/00453; the pyrazolo [4,3 d]pyrimidin-7-ones disclosed in WO 98/49166; the pyrazolo [4,3-d]pyrimidin 25 7-ones disclosed in WO 99/54333; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in EP 0995751; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in WO 00/24745; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in EP 0995750; the hexahydropyrazino [2',1':6,1]pyrido [3,4-b]indole-1,4-diones disclosed in WO95/19978; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in WO 30 00/27848; the imidazo[5,1-f][1,2,4]triazin-ones disclosed in EP 1092719 and WO 99/24433; the bicyclic compounds disclosed in WO 93/07124; the pyrazolo[4,3-d]pyrimidin-7-ones disclosed in WO 01/27112; the pyrazolo [4,3 d]pyrimidin-7-ones disclosed in WO 01/27113; the compounds disclosed in EP WO 2007/072169 PCT/IB2006/003683 6 1092718; the compounds disclosed in EP 1092719; the tricyclic compounds disclosed in EP 1241170; the alkyl sulphone compounds disclosed in WO 02/074774; the compounds disclosed in WO 02/072586; the compounds disclosed in WO 02/079203; and the compounds disclosed in WO 02/074312; 5 (iv) 5-[2-ethoxy-5-(4-methyl-l1-piperazinylsulphonyl)phenyl]-l1-methyl-3-n-propyl 1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil) also known as 1 [[3-(6,7-dihydro-l1-methyl-7-oxo-3-propyl-l1H-pyrazolo[4,3-d]pyrimidin-5-yl) 4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP 0463756); 5-(2-ethoxy 5-morpholinoacetylphenyl)- 1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3 10 d]pyrimidin-7-one (see EP 0526004); 3-ethyl-5-[5-(4-ethylpiperazin-1 ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro- 7
H
pyrazolo[4,3-d]pyrimidin-7-one (see WO 98/49166); 3-ethyl-5-[5-(4 ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin- 2 yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO99/54333), 15 (+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R) methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3 d]pyrimidin-7-one, also known as 3-ethyl-5- { 5-[4-ethylpiperazin- 1 ylsulphonyl]-2-([(1R)-2-methoxy- 1-methylethyl]oxy)pyridin-3-yl }-2-methyl 2,6-dihydro-7H-pyrazolo[4,3-d] pyrimidin-7-one (see WO 99/54333); 5-[2 20 ethoxy-5-(4-ethyl-piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2-methoxy ethyl]-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one, also known as 1-{6 ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[ 4
,
3 d]pyrimidin-5-yl]-3-pyridylsulphonyl}-4-ethylpiperazine (see WO 01/27113, Example 8) [the free base and besylate salt are of particular interest]; 5-[2-iso 25 butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(1 methylpiperidin-4-yl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27113, Example 15); 5-[2-Ethoxy-5-(4-ethylpiperazin- 1 ylsulphonyl)pyridin-3-yl]-3-ethyl-2-phenyl-2,6-dihydro-7H-pyrazolo[4,3 d]pyrimidin-7-one (see WO 01/27113, Example 66); 5-(5-Acetyl-2-propoxy-3 30 pyridinyl)-3-ethyl-2-(1-isopropyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[ 4
,
3 d]pyrimidin-7-one (see WO 01/27112, Example 124); 5-(5-Acetyl-2-butoxy-3 pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3 d]pyrimidin-7-one (see WO 01/27112, Example 132); (6R,12aR)- WO 2007/072169 PCT/IB2006/003683 7 2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4 methylenedioxyphenyl)pyrazino[2', 1':6,1]pyrido[3,4-b]indole-1,4-dione (tadalafil, IC-351, Cialis®), i.e. the compound of examples 78 and 95 of WO95/19978, as well as the compound of examples 1, 3, 7 and 8; 2-[2-ethoxy 5 5-(4-ethyl-piperazin-1-yl-l1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H imidazo[5,1-fJ[1,2,4]triazin-4-one (vardenafil, LEVITRA ®) also known as 1 [[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4 ethoxyphenyl]sulphonyl]-4-ethylpiperazine, i.e. the compound of examples 20, 19, 337 and 336 of WO99/24433; the compound of example 11 of 10 WO93/07124 (EISAI); compounds 3 and 14 from Rotella D P, J. Med. Chem., 2000, 43, 1257; 4-(4-chlorobenzyl)amino-6,7,8-trimethoxyquinazoline; N-[[3 (4,7-dihydro-l1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]-pyrimidin-5-yl)-4 propxyphenyl]sulfonyl]- 1 -methyl2-pyrrolidinepropanamide ["DA-8159" (Example 68 of WO00/27848)]; and 7,8-dihydro-8-oxo-6-[2-propoxyphenyl] 15 1H-imidazo[4,5-g]quinazoline and 1-[3-[ 1-[(4-fluorophenyl)methyl]-7,8 dihydro-8-oxo- 1H-imidazo[4,5-g]quinazolin-6-yl]-4 propoxyphenyl]carboxamide; (v) 4-bromo-5-(pyridylmethylamino)-6-[3-(4-chlorophenyl)-propoxy] 3(2H)pyridazinone; 1-[4-[(1,3-benzodioxol-5-ylmethyl)amiono]-6-chloro-2 20 quinozolinyl]-4-piperidine-carboxylic acid, monosodium salt; (+)-cis 5,6a,7,9,9,9a-hexahydro-2-[4-(trifluoromethyl)-phenylmethyl-5-methyl cyclopent-4,5]imidazo[2,1-b]purin-4(3H)one; furazlocillin; cis-2-hexyl-5 methyl-3,4,5,6a,7,8,9,9a- octahydrocyclopent[4,5]-imidazo[2,1-b]purin-4-one; 3-acetyl- 1-(2-chlorobenzyl)-2-propylindole-6- carboxylate; 3-acetyl- 1-(2 25 chlorobenzyl)-2-propylindole-6-carboxylate; 4-bromo-5-(3 pyridylmethylamino)-6-(3-(4-chlorophenyl) propoxy)-3- (2H)pyridazinone; I methyl-5(5-morpholinoacetyl-2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro- 7H pyrazolo(4,3-d)pyrimidin-7-one; 1-[4-[(1,3-benzodioxol-5-ylmethyl)arnino]-6 chloro-2- quinazolinyl]-4-piperidinecarboxylic acid, monosodium salt; 30 Pharmaprojects No. 4516 (Glaxo Wellcome); Pharmaprojects No. 5051 (Bayer); Pharmaprojects No. 5064 (Kyowa Hakko; see WO 96/26940); Pharmaprojects No. 5069 (Schering Plough); GF-196960 (Glaxo Wellcome); WO 2007/072169 PCT/IB2006/003683 8 E-8010 and E-4010 (Eisai); Bay-38-3045 & 38-9456 (Bayer); FR229934 and FR226807 (Fujisawa); and Sch-51866; and pharmaceutically acceptable salts thereof. 5 Preferred PDE5 inhibitors include: 5-[2-ethoxy-5-(4-methyl-1 piperazinylsulphonyl)phenyl]-l-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3 d]pyrimidin-7-one (sildenafil), particularly sildenafil citrate; (6R,12aR)-2,3,6,7,12,12a hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1':6,1 ]pyrido[3,4 b]indole-1,4-dione (IC-351 or tadalafil); 2-[2-ethoxy-5-(4-ethyl-piperazin-1l-yl-1 10 sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil); 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H pyrazolo[4,3-d]pyrimidin-7-one; 5-(5-Acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(1 isopropyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-[2-ethoxy-5 (4-ethyl-piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2-methoxy-ethyl]-2,6-dihydro 15 pyrazolo[4,3-d]pyrimidin-7-one; 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2 (hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide (TA-1790); 3-(1-methyl-7-oxo-3-propyl-6,7-dihydro- 1H-pyrazolo[4,3-d]pyrimidin-5-yl) N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide (DA 8159); and pharmaceutically acceptable salts thereof. 20 More preferably, the PDE5 inhibitor is selected from sildenafil, tadalafil, vardenafil, DA 8159 and 5-[2-ethoxy-5-(4-ethyl-piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2 methoxy-ethyl]-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one, and pharmaceutically acceptable salts thereof. 25 Most preferably the PDE5 inhibitor is selected from sildenafil, 5-[2-ethoxy-5-(4-ethyl piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2-methoxy-ethyl]-2,6-dihydro pyrazolo[4,3-d]pyrimidin-7-one, and pharmaceutically acceptable salts thereof. Sildenafil citrate is a preferred salt of sildenafil. The besylate salt is a preferred salt of 5-[2-ethoxy 30 5-(4-ethyl-piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2-methoxy-ethyl]-2,6 dihydro-pyrazolo[4,3-d]pyrimidin-7-one.
WO 2007/072169 PCT/IB2006/003683 9 Muscarinic antagonists suitable for use in the invention can be selective for M 3 receptors or they can be non-selective, exhibiting antagonism at MI, M 2 and M 3 . Antagonists selective for the M 3 receptor are preferred. 5 Specific muscarinic antagonists include: atropine fluvoxate; hyoscine; oxybutynin; 10 darifenacin; tolterodine and the other compounds disclosed in International Patent Application WO 89/06644; (+)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine and the other compounds disclosed in WO 94/11337; 15 propantheline propiverine trospium; solifenacin; fesoterodine and the other compounds disclosed in WO 99/58478; 20 the compounds disclosed in WO 98/05641; and pharmaceutically acceptable salts thereof. Especially preferred are: darifenacin; 25 oxybutynin; tolterodine; (+)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine; solifenacin; fesoterodine; 30 and pharmaceutically acceptable salts thereof.
WO 2007/072169 PCT/IB2006/003683 10 Tolterodine (especially in the form of its tartrate salt) and fesoterodine (or a pharmaceutically acceptable salt thereof, such as the hydrogen fumarate salt) are of particular interest. 5 According to a further aspect of the invention, there is provided a pharmaceutical formulation comprising: a PDE5 inhibitor; and a muscarinic antagonist; provided that the PDE5 inhibitor is not sildenafil or a salt thereof when the muscarinic 10 antagonist is scopolamine or a salt thereof. The combinations of the invention may have the advantage that the two components act synergistically to produce an unexpectedly potent effect and/or an unexpectedly favourable level of side-effects in comparison with the corresponding total dosage of one 15 of the components on its own. In addition, the combinations of the invention may have a longer duration of action, improved selectivity, or other more useful properties compared with the prior art. The component compounds of the combinations of the present invention are prepared by 20 methods well known to those skilled in the art. Specifically, the patents, patent applications and publications, mentioned above, each of which is hereby incorporated by reference, exemplify compounds which can be used in combinations, pharmaceutical compositions, methods and kits in accordance with the present inventions, and refer to methods of preparing those compounds. 25 Pharmaceutically acceptable salts of the compounds suitable for use in the invention include the acid addition and base salts thereof. For a review on suitable salts, see "Handbook of Pharmaceutical Salts: Properties, 30 Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). A pharmaceutically acceptable salt of a compound suitable for use in the present invention may be readily prepared by mixing together solutions of the compound and the WO 2007/072169 PCT/IB2006/003683 11 desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the salt may vary from completely ionised to almost non-ionised. 5 The compounds suitable for use in the combinations of the present invention include the compounds as hereinbefore defined, polymorphs, prodrugs, and isomers thereof (including optical, geometric and tautomeric isomers). Usually, compounds for use in the invention will be administered as a formulation in 10 association with one or more pharmaceutically acceptable excipients. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form. The compounds may be present in the same dosage form in accordance with the first aspect of the invention, or they may be present in separate dosage forms, for 15 example as encompassed by the fourth aspect of the invention. Pharmaceutical compositions suitable for delivering the compounds suitable for use in the combinations of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation 20 may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995). Preferably, the compounds suitable for use in the combinations of the invention are administered orally, and therefore the formulations, uses, methods and products of the 25 invention will be suitable for, or involve, oral administration. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth. 30 Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including WO 2007/072169 PCT/IB2006/003683 12 muco-adhesive), ovules, sprays and liquid formulations. Tablets and capsules are preferred. Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations 5 may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet. 10 The compounds suitable for use in the combinations of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001). 15 For tablet dosage forms, depending on dose, the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, 20 microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form. Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable 25 binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium 30 phosphate dihydrate. Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface WO 2007/072169 PCT/IB2006/003683 13 active agents may comprise from 0.2 wt% to 5 wt% of the tablet, and glidants may comprise from 0.2 wt% to 1 wt% of the tablet. Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, 5 zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet. Other possible ingredients include anti-oxidants, colourants, flavouring agents, 10 preservatives and taste-masking agents. Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant. 15 Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated. 20 The formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets, Vol. 1", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-8247 6918-X). 25 Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Suitable modified release formulations for the purposes of the invention are described in 30 US Patent No. 6,106,864 when the muscarinic antagonist is darifenacin. Suitable modified release formulations of tolterodine are described in WO 00/12069, WO 00/27364, and WO 01/34139. These formulations may be adapted to include the second WO 2007/072169 PCT/IB2006/003683 14 active ingredient of a combination according to the invention. Such modified release capsules for oral administration are preferred. Details of other suitable release technologies such as high energy dispersions and osmotic 5 and coated particles are to be found in Verma et al, Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298. The compounds suitable for use in the combinations of the invention may also be 10 administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques. 15 Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as 20 sterile, pyrogen-free water. The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art. 25 The solubility of compounds used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents. 30 Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted WO 2007/072169 PCT/IB2006/003683 15 depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres. The compounds suitable for use in the combinations of the invention may also be 5 administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, 10 polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated see, for example, J Pharm Sci, 88 (10), 955-958 by Finnrin and Morgan (October 1999). Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. PowderjectTM, 15 BiojectTM, etc.) injection. Formulations for topical administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. 20 The compounds suitable for use in the combinations of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry 25 powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin. 30 The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending WO 2007/072169 PCT/IB2006/003683 16 release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid. Prior to use in a dry powder or suspension formulation, the drug product is micronised to 5 a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying. 10 Capsules (made, for example, from gelatin or HPMC), blisters and cartridges for use in an inhaler or insuffiator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include 15 dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose. A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 ptg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1 .l to 1 00gl. A typical formulation 20 may comprise a compound of the invention, propylene glycol, sterile water, ethanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol. Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or 25 saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration. Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, poly(DL-lactic-coglycolic acid (PGLA). 30 Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
WO 2007/072169 PCT/IB2006/003683 17 The compounds suitable for use in the combinations of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate. 5 Formulations for rectal/vaginal administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. 10 The compounds suitable for use in the combinations of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration. 15 Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most 20 commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO 98/55148. In accordance with the fourth aspect of the invention, two or more pharmaceutical 25 compositions may conveniently be combined in the form of a kit suitable for co administration of the compositions. Thus the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound as hereinbefore described in 30 accordance with the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
WO 2007/072169 PCT/IB2006/003683 18 The kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided 5 with a so-called memory aid. For the avoidance of doubt, references herein to "treatment" include references to curative, palliative and prophylactic treatment. 10 Suitable dosages of the compounds for use in the combinations of the invention will depend on the compound concerned, the condition to be treated and the weight of the patient. However, in general, a suitable daily dose of muscarinic antagonist is in the range 0.1-100 mg: for example 0.1-4 mg for tolterodine tartrate; and 0.2-8mg for fesoterodine, or a pharmaceutically acceptable salt thereof. In general, a suitable daily dose of PDE5 15 inhibitor is in the range 0.1-120 mg: for example 2.5-100 mg for sildenafil citrate; 0.5-200 mg for 5-[2-ethoxy-5-(4-ethyl-piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2 methoxy-ethyl]-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one, or a pharmaceutically acceptable salt thereof; and 0.5-20 mg for vardenafil, tadalafil, and pharmaceutically acceptable salts thereof. 20 Specific preferred combinations of the invention are: * sildenafil, or a pharmaceutically acceptable salt thereof + tolterodine, or a pharmaceutically acceptable salt thereof; 25 * sildenafil, or a pharmaceutically acceptable salt thereof + fesoterodine, or a pharmaceutically acceptable salt thereof; * 5-[2-ethoxy-5-(4-ethyl-piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2 methoxy-ethyl]-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one, or a pharmaceutically acceptable salt thereof + tolterodine, or a pharmaceutically 30 acceptable salt thereof; and * 5-[2-ethoxy-5-(4-ethyl-piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2 methoxy-ethyl]-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one, or a WO 2007/072169 PCT/IB2006/003683 19 pharmaceutically acceptable salt thereof + fesoterodine, or a pharmaceutically acceptable salt thereof. The typical weight ratio of active ingredients [PDE5 inhibitor:muscarinic antagonist] in 5 these specific preferred combinations may vary from 1:10 to 10:1, for example 1:4 to 4:1, 1:3 to 3:1, 1:2 to 2:1, and includes 1:1. Example 1 Immediate release tablet containing tolterodine and sildenafil 10 Tablets having the following composition are prepared using conventional methods: Core Tolterodine L-tartrate 2.0 mg 15 Sildenafil citrate 25.0 mg cellulose, microcrystalline 53.4 mg calcium hydrogen phosphate dihydrate 18.0 mg sodium starch glycollate 6.0 mg magnesium stearate 0.4 mg 20 colloidal anhydrous silica 0.2 mg Coating Methylhydroxypropyl cellulose 1.5 mg cellulose, microcrystalline 0.3 mg 25 stearic acid 0.6 mg titanum dioxide E 171 0.6 mg Example 2 Immediate release tablet containing tolterodine and 5-[2-ethoxy-5-(4-ethyl 30 piperazine-l-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2-methoxy-ethyl]-2, 6 -dihydro pyrazolo[4,3-d]pyrimidin-7-one Tablets having the following composition are prepared using conventional methods: WO 2007/072169 PCT/IB2006/003683 20 Core Tolterodine L-tartrate 2.0 mg 5-[2-ethoxy-5-(4-ethyl-piperazine- 1 5 sulphonyl)-pyridin-3-yl]-3-ethyl-2 [2-methoxy-ethyl]-2,6-dihydro pyrazolo[4,3-d]pyrimidin-7-one 5.0 mg cellulose, microcrystalline 53.4 mg calcium hydrogen phosphate dihydrate 18.0 mg 10 sodium starch glycollate 6.0 mg magnesium stearate 0.4 mg colloidal anhydrous silica 0.2 mg Coating 15 Methylhydroxypropyl cellulose 1.5 mg cellulose, microcrystalline 0.3 mg stearic acid 0.6 mg titanum dioxide E 171 0.6 mg 20 Example 3 Immediate release tablet containing fesoterodine and 5-[2-ethoxy-5-(4-ethyl piperazine-l-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2-methoxy-ethyl]-2, 6 -dihydro pyrazolo[4,3-d]pyrimidin-7-one 25 Tablets having the following composition are prepared using conventional methods: Core Fesoterodine hydrogen fumarate 2.0 mg 5-[2-ethoxy-5-(4-ethyl-piperazine- 1 30 sulphonyl)-pyridin-3-yl]-3-ethyl-2 [2-methoxy-ethyl]-2,6-dihydro pyrazolo[4,3-d]pyrimidin-7-one, besylate salt 5.0 mg WO 2007/072169 PCT/IB2006/003683 21 cellulose, microcrystalline 53.4 mg calcium hydrogen phosphate dihydrate 18.0 mg sodium starch glycollate 6.0 mg magnesium stearate 0.4 mg 5 colloidal anhydrous silica 0.2 mg Coating Methylhydroxypropyl cellulose 1.5 mg cellulose, microcrystalline 0.3 mg 10 stearic acid 0.6 mg titanum dioxide E 171 0.6 mg Example 4 Controlled release capsule containing tolterodine and sildenafil 15 Based on Example 1 of WO 00/27364, controlled release beads containing tolterodine tartrate are produced having the following structure: Core: Starch-containing sugar sphere of about 0.8 mm diameter (commercially 20 available); comprises 73 % w/w of the final bead; purpose: coating substrate; First layer: SureleaseTM "sealcoat" (SureleaseTM is an aqueous film-coating dispersion, about 25% solids, consisting primarily of ethylcellulose plasticized with fractionated 25 coconut oil, and manufactured by Colorcon, Inc, USA); comprises about 12 % w/w of the final bead; purpose: to provide more consistent core surface; during drug release phase maximize time that drug is saturated inside bead and minimize osmotic effects; control drug release rate together with the third layer; 30 Second layer: Tolterodine L-tartrate/hydroxypropylmethylcellulose (HPMC); comprises about 3 % w/w of the final bead; ratio of Tolterodine:HPMC is 5:1; purpose: drug supply; WO 2007/072169 PCT/IB2006/003683 22 Third layer: SureleaseTM/HPMC; comprises about 12 % w/w of the final bead; ratio of SureleaseTM:HPMC is 6:1; purpose: drug release rate control; 5 The beads with a three-layer coating having the above characteristics were prepared as follows: 1200 g of sugar spheres, 20-25 mesh, were charged into a Wurster fluid bed and sequentially coated at a nominal product temperature of 36 to 40 0 C with the following 10 three coating liquids: -(1) a SureleaseTM sealcoating liquid prepared by mixing 788 g of SureleaseTM with 563 g of purified water; -(2) a drug-containing solution prepared by first dissolving 35.0 g of tolterodine L-tartrate in 2190 g of purified water, and then mixing the solution with 6.6 g of 15 hydroxypropylmethyl cellulose (HPMC) 5 cP; and -(3) a sustained release coating liquid prepared by mixing 29 g of HPMC 5 cP with 375 g of purified water, and then mixing with 695 g of SureleaseM. Controlled release beads containing sildenafil citrate are prepared in an analogous 20 manner, but substituting the 35 g of tolterodine tartrate in coating liquid (2) with 70 mg sildenafil tartrate. After tray drying for 3 hours at 70oC, the coated spheres are filled into size #4 or size #3 hard gelatin capsules to obtain capsules containing 2 mg tolterodine L-tartrate and 4 mg 25 sildenafil citrate of the composition: Tolterodine L-tartrate 2.0 mg Sildenafil citrate 4.0 mg sugar spheres, 20-25 mesh 137.2 mg SureleaseTM - 42.4 mg 30 HPMC 5cP 4.0 mg Optionally, a fourth layer may be applied to the beads before drying by Wurster coating.
WO 2007/072169 PCT/IB2006/003683 23 Fourth layer: HPMC; comprises about 1 % w/w of the final bead; purpose: decrease tackiness of beads for subsequent processing (curing and capsule filling). 5 In the case of the above described beads such a fourth layer may be applied with a coating solution prepared by dissolving 16.4 g of HPMC in 234 g of water. Biological Example A 10 Experimental models of BPH involving bladder outflow obstruction have been developed in a number of animal species. These models, which involve the placement of a ligature or disc around the urethra, mimic prostatic occlusion of the urethra and result in the appearance of non-voiding or unstable contractions of the bladder on cystometrical evaluation [Levin et al (2000) In: Prostatic Diseases (eds Lepor and Oesterling), WB 15 Saunders & Co.]. In addition these models reproduce many of the LUT symptoms associated with multiple forms of OAB including increased voiding frequency and decreased functional voiding capacity. The beneficial effects of the combinations of the invention may be demonstrated in the 20 following mouse model of LUTS associated with BPH. A mouse model of short term urethral obstruction has been characterised and demonstrated to show increased voiding frequency and the presence of non-voiding contractions, coupled with a reduced bladder capacity (Schroder et al. (2003) J.Urol. 170, 25 1017-1021). The advantage of this model is that it closely mimics the bladder dysfunction observed in BPH patients and LUTS associated with other overactive bladder conditions. Materials and Methods 30 Animals: DBA/1LacJ mice are used for the studies, available from Charles River Laboratories, UK. After arrival, the mice are housed for 6 weeks under identical WO 2007/072169 PCT/IB2006/003683 24 conditions under a 12 hours light/dark photocycle, food and water are provided ad libitum. The mice are randomly divided into 3 groups each. One third receives bladder outlet 5 obstruction (BOO) as described below, one third receives sham surgery. The remaining mice serve as unoperated controls. Surgical procedure: The mice in the BOO group are anaesthetized with ketamine (Ketalar®, Parke Davis, Barcelona, Spain; 100 mg/kg IP) and xylazine (Rompun®, Bayer, 10 Leverkusen, Germany, 15 mg/kg IP). The obstruction is created by a standardized method as described in Schroder et al 2003 J.Urol 170, 1017-1021. Sham operated animals receive surgery similarly, without tying the obstruction. At day 5 after the obstruction a polyethylene catheter (PE, ID 0.38 mm, OD 0.61 mm) 15 with a small cuff is inserted in the bladder dome and secured with a purse-string suture (7 0 silk). The obstructing ligature remains in place. The catheter is tunnelled subcutaneously, led out on the back of the neck, and surgically secured. Control animals receive the bladder catheter 2 days prior to cystometry. 20 Cystometry: Two days after insertion of the catheter (7 days after creation of the obstruction), the cystometric investigation is performed without any anaesthesia or restraint. The mice are placed into a metabolic cage (Gazzada, Buguggiatade, Italy). The bladder catheter is connected to a pressure transducer, which in turn is connected to a Grass 7E Polygraph recorder. The bladder is continuously filled with saline at room 25 temperature by means of a microinjecton pump (CMA 100, Carnegie Medicine, Solna, Sweden), at a filling speed of 25gl/min. The amount of voided urine is measured by means of a fluid collector, connected to a force displacement transducer (FT 03 D; Grass instrument Co., MA, USA). After a 30 stabilization period of 60-80 minutes, in which the bladder is continuously filled, reproducible voiding patterns are achieved and recorded over a period of 30 minutes. The following parameters are measured: Micturition interval (time between 2 voids), baseline pressure (lowest pressure between 2 voids), threshold pressure (pressure immediately WO 2007/072169 PCT/IB2006/003683 25 before micturition was initiated), micturition pressure (maximum voiding pressure), and micturition volume. Residual urine is emptied manually 3 times at the end of the cystometry and measured. Bladder capacity is calculated as the amount of saline infused into the bladder between 2 voids, plus the average amount of residual urine. 5 The animals are continuously observed in order to distinguish between moving artifacts and non-voiding bladder contractions. The surface of the collecting-funnel under the grid of the metabolic cage was sprayed with a thin layer of silicone. 10 Biological Example B The beneficial effects of the combinations of the invention may be demonstrated in the following experimental model which evaluates the effects of test substances on lower urinary tract function in the guinea-pig adapted from Doe et al (Eur J Pharmacol. 383: 15 137-303, 1999). Materials and Methods Animals: Female Hartley guinea pigs (body weight 300-350 grams). 20 Surgical procedure: The animals are anaesthetized with urethane (1.5 g/kg intraperitoneally) given as a divided dose of 80% initially and 20% 15 min later. Body temperature is maintained at 37±2 0 C throughout the experiment. The bladder is exposed through a lower abdominal incision and a polyethylene catheter with a small cuff is 25 inserted in the bladder dome and secured with a purse-string suture. The ureters are then ligatured. The bladder is replaced under the abdominal wall and the catheter is connected via a T-tube to a pressure transducer in order to measure intravesical pressure. The trachea is cannulated. The jugular vein is cannulated to allow administration of test compounds and the femoral artery is cannulated in order to collect plasma sample. 30 Cystometry: A series of filling cystometry cycles are performed throughout the experimental measurement period to establish baseline parameters and determine drug effect. Before each cystometry cycle, the bladder is emptied manually. Saline at room WO 2007/072169 PCT/IB2006/003683 26 temperature is then infused continuously into the bladder via the catheter at a flow rate of 600 pL/min until a micturition occurs. The following micturition parameters are measured during each cystometry cycle:- Micturition Pressure (MP, the pressure in the bladder during voiding) and Threshold Volume (ThV, volume at which micturition 5 occurs, mL). Evaluation of drug effect: After the determination of baseline parameters (mean of 3 micturition cycles), test substance or vehicle is administered continuously for 60 minutes. At the end of the drug infusion period, the effect of drug on cystometry parameters is 10 determined by taking an average of the measurements made in two micturition cycles. For combination studies, the respective doses of the test compounds are infused together over a 60 min period following the measurement of baseline parameters. Results: 15 The muscarinic antagonist, oxybutynin (3.18 mg/kg) produced a small increase in micturition pressure, whereas the PDE5 inhibitor, 3-ethyl-5-[5-(4-ethylpiperazin-1 ylsulphonyl)-2-n-propoxyphenyl]- 1-(pyridin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3 d]pyrimidin-7-one (referred to herein as "Compound A", see Example 2, WO 98/49166, 20 0.11 mg/kg, 0.32 mg/kg) produced a small reduction in micturition pressure. The combination of oxybutynin (3.18 mg/kg) plus Compound A (0.32 mg/kg) produced a greater reduction in micturition pressure than observed with Compound A (0.32 mg/kg) alone. Thus these data appear to imply a synergistic effect of oxybutynin and the higher dose of Compound A tested on micturition pressure. 25 The effects of oxybutynin (3.18 mg/kg) and Compound A (0.11 mg/kg, 0.32 mg/kg) alone and in combination on threshold volume are shown in the Table 1. Table 1: Effects of Oxybutynin and Compound A on Cystometry Parameters in the 30 Anaesthetized Guinea-pig WO 2007/072169 PCT/IB2006/003683 27 Treatment % Change in % Change in Micturition Threshold Pressure Volume Oxybutynin + 3.2 + 18.9 (3.18 mg/kg) Compound A -6.7 -2.7 (0.11 mg/kg) Compound A -6 + 11.4 (0.32 mg/kg) Oxybutynin (3.18 mg/kg) +1.5 +10.4 + Compound A (0.11 mg/kg) Oxybutynin (3.18 mg/kg) + -13.3 -4 Compound A (0.32 mg/kg)
Claims (12)
1. A pharmaceutical formulation comprising: a PDE5 inhibitor; and 5 a muscarinic antagonist.
2. A formulation as claimed in claim 1, wherein the PDE5 inhibitor is selected from: sildenafil; tadalafil; 10 vardenafil;
5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H pyrazolo[4,3-d]pyrimidin-7-one; 5-(5-Acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(1-isopropyl-3-azetidiniyl)-2,6-dihydro-7H pyrazolo[4,3-d]pyrimidin-7-one; 15 5-[2-ethoxy-5-(4-ethyl-piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2-methoxy ethyl]-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one; 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N (pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide (TA-1790); 3-( 1 -methyl-7-oxo-3-propyl-6,7-dihydro- 1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1 20 methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide (DA 8159); and pharmaceutically acceptable salts thereof. 3. A formulation as claimed in claim 1 or claim 2, wherein the PDE5 inhibitor is selected from: 25 sildenafil; tadalafil; vardenafil; DA-8159; and 5-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2-methoxy-ethyl] 30 2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one; and pharmaceutically acceptable salts thereof. WO 2007/072169 PCT/IB2006/003683 29 4. A formulation as claimed in any one of the preceding claims, wherein the PDE5 inhibitor is selected from: sildenafil; 5-[2-ethoxy-5-(4-ethyl-piperazine- 1-sulphonyl)-pyridin-3-yl]-3-ethyl-2-[2-methoxy 5 ethyl]-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one; and pharmaceutically acceptable salts thereof. 5. A formulation as claimed in any one of the preceding claims, wherein the muscarinic antagonist is selected from: 10 atropine; fluvoxate; hyoscine; oxybutynin; darifenacin; 15 tolterodine; (+)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine; propantheline; propiverine; trospium; 20 solifenacin; fesoterodine; and pharmaceutically acceptable salts thereof.
6. A formulation as claimed in any one of the preceding claims, wherein the 25 muscarinic antagonist is selected from: darifenacin; oxybutynin; tolterodine; (+)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine; 30 solifenacin; fesoterodine; and pharmaceutically acceptable salts thereof. WO 2007/072169 PCT/IB2006/003683 30
7. A formulation as claimed in any one of the preceding claims, wherein the muscarinic antagonist is selected from tolterodine, fesoterodine, and their pharmaceutically acceptable salts. 5 8. Use of a PDE5 inhibitor and a muscarinic antagonist, as defined in any one of claims 1 to 7, in the manufacture of a medicament for the treatment of LUTS.
9. A method of treatment of LUTS, comprising simultaneous, separate or sequential administration of a PDE5 inhibitor and a muscarinic antagonist, as defined in any one of 10 claims 1 to 7, to a patient in need of such treatment.
10. Pharmaceutical products comprising a PDE5 inhibitor and a muscarinic antagonist, as defined in any one of claims 1-7, as a combined preparation for simultaneous, separate or sequential use in the treatment of LUTS. 15
11. The use, method or products as claimed in any one of claims 8 to 10, wherein the LUTS is urgency, frequency, nocturia or urge incontinence.
12. The formulations, use, method or products as claimed in any one of the preceding 20 claims, wherein the PDE5 inhibitor is sildenafil, or a pharmaceutically acceptable salt thereof, and the muscarinic antagonist is tolterodine, or a pharmaceutically acceptable salt thereof.
13. The formulations, use, method or products as claimed in any one of claims 1 to 12, 25 wherein the PDE5 inhibitor is sildenafil, or a pharmaceutically acceptable salt thereof, and the muscarinic antagonist is fesoterodine, or a pharmaceutically acceptable salt thereof.
14. The formulations, use, method or products as claimed in any one of claims 1 to 12, wherein the PDE5 inhibitor is 5-[2-ethoxy-5-(4-ethyl-piperazine- 1-sulphonyl)-pyridin-3 30 yl]-3-ethyl-2-[2-methoxy-ethyl]-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one, or a pharmaceutically acceptable salt thereof, and the muscarinic antagonist is tolterodine, or a pharmaceutically acceptable salt thereof. WO 2007/072169 PCT/IB2006/003683 31
15. The formulations, use, method or products as claimed in any one of claims 1 to 12, wherein the PDE5 inhibitor is 5-[2-ethoxy-5-(4-ethyl-piperazine-l1-sulphonyl)-pyridin-3 yl]-3-ethyl-2-[2-methoxy-ethyl]-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one, or a pharmaceutically acceptable salt thereof, and the muscarinic antagonist is fesoterodine, or 5 a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75262505P | 2005-12-20 | 2005-12-20 | |
US60/752,625 | 2005-12-20 | ||
US75772006P | 2006-01-09 | 2006-01-09 | |
US60/757,720 | 2006-01-09 | ||
PCT/IB2006/003683 WO2007072169A2 (en) | 2005-12-20 | 2006-12-19 | Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2006327882A1 true AU2006327882A1 (en) | 2007-06-28 |
Family
ID=37946766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006327882A Abandoned AU2006327882A1 (en) | 2005-12-20 | 2006-12-19 | Pharmaceutical combination for the treatment of LUTS comprising a PDE5 inhibitor and a muscarinic antagonist |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080318982A1 (en) |
EP (1) | EP1965863A2 (en) |
JP (1) | JP2007169278A (en) |
KR (1) | KR20080076961A (en) |
AR (1) | AR058119A1 (en) |
AU (1) | AU2006327882A1 (en) |
BR (1) | BRPI0620234A2 (en) |
CA (1) | CA2634019A1 (en) |
RU (1) | RU2008120332A (en) |
TW (1) | TW200733975A (en) |
WO (1) | WO2007072169A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7807715B2 (en) * | 2006-06-09 | 2010-10-05 | Ucb Pharma Gmbh | Pharmaceutical compositions comprising fesoterodine |
EP2175843B1 (en) * | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
WO2009056232A2 (en) * | 2007-10-30 | 2009-05-07 | Bayer Schering Pharma Aktiengesellschaft | Combination of pde5 inhibitors with muscarinic receptor antagonists |
EP2106792A1 (en) * | 2008-04-02 | 2009-10-07 | Pelvipharm | Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder |
EA023529B1 (en) * | 2009-02-27 | 2016-06-30 | КРКА, д.д., НОВО МЕСТО | Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts for oral administration |
EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
EP2316432A1 (en) * | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Compound containing fesoterodine and roughage |
KR20110062943A (en) * | 2009-12-04 | 2011-06-10 | 주식회사종근당 | Agent for prevention or treatment of benign prostatic hyperplasia containing quinazoline derivative |
US20130323288A1 (en) | 2010-07-08 | 2013-12-05 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
TWI590821B (en) | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | Solid molecular dispersion |
EP2508175A1 (en) * | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof |
US20130236544A1 (en) * | 2012-03-08 | 2013-09-12 | Dr. Reddy's Laboratories Ltd. | Stable pharmaceutical compositions of fesoterodine |
CA2904416A1 (en) * | 2013-03-07 | 2014-09-12 | Amneal Pharmaceuticals, LLC | Stabilization of moisture-sensitive drugs |
US20140271847A1 (en) * | 2013-03-13 | 2014-09-18 | SatisPharma, LLC | Formulations and methods for rapid penile erections |
US10792326B2 (en) | 2013-06-28 | 2020-10-06 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
KR102239291B1 (en) * | 2013-06-28 | 2021-04-14 | 한미약품 주식회사 | Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof |
JP2015133989A (en) * | 2015-04-28 | 2015-07-27 | 重泉 達志 | health food |
US10335453B2 (en) * | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8800207D0 (en) * | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | NEW AMINES, THEIR USE AND MANUFACTURING |
SE9203318D0 (en) * | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | NOVEL 3,3-DIPHENYL PROPYLAMINES, THEIR USE AND PREPARATION |
WO1998049166A1 (en) * | 1997-04-25 | 1998-11-05 | Pfizer Limited | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
AU3621097A (en) * | 1997-07-09 | 1999-02-08 | Wolf-Georg Forssmann | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases |
EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
IL132406A0 (en) * | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
US6642274B1 (en) * | 1999-09-09 | 2003-11-04 | Gary W. Neal | Methods and compositions for preventing and treating prostate disorders |
TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
SK4562002A3 (en) * | 1999-10-11 | 2003-04-01 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the manufacture of a medicament for the treatment of benign prostatic hyperplasia |
US20040180958A1 (en) * | 2002-12-13 | 2004-09-16 | Taylor Charles Price | Method of treatment |
-
2006
- 2006-12-19 AU AU2006327882A patent/AU2006327882A1/en not_active Abandoned
- 2006-12-19 RU RU2008120332/15A patent/RU2008120332A/en unknown
- 2006-12-19 US US12/093,358 patent/US20080318982A1/en not_active Abandoned
- 2006-12-19 JP JP2006341662A patent/JP2007169278A/en active Pending
- 2006-12-19 EP EP06821077A patent/EP1965863A2/en not_active Withdrawn
- 2006-12-19 BR BRPI0620234-9A patent/BRPI0620234A2/en not_active IP Right Cessation
- 2006-12-19 TW TW095147592A patent/TW200733975A/en unknown
- 2006-12-19 CA CA002634019A patent/CA2634019A1/en not_active Abandoned
- 2006-12-19 AR ARP060105610A patent/AR058119A1/en unknown
- 2006-12-19 WO PCT/IB2006/003683 patent/WO2007072169A2/en active Application Filing
- 2006-12-19 KR KR1020087014835A patent/KR20080076961A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2007072169A2 (en) | 2007-06-28 |
TW200733975A (en) | 2007-09-16 |
JP2007169278A (en) | 2007-07-05 |
BRPI0620234A2 (en) | 2011-11-01 |
CA2634019A1 (en) | 2007-06-28 |
EP1965863A2 (en) | 2008-09-10 |
WO2007072169A3 (en) | 2007-11-01 |
RU2008120332A (en) | 2010-01-27 |
AR058119A1 (en) | 2008-01-23 |
KR20080076961A (en) | 2008-08-20 |
US20080318982A1 (en) | 2008-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080318982A1 (en) | Pharmaceutical Combination for the Treatment of Luts | |
US20080261995A1 (en) | Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor | |
US20040122010A1 (en) | Treatment of neuropathy | |
HUE028008T2 (en) | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | |
JP2008509900A (en) | Formulation of selective noradrenaline reuptake inhibitor and PDEV inhibitor | |
JP2008509900A6 (en) | Formulation of selective noradrenaline reuptake inhibitor and PDEV inhibitor | |
KR20050042154A (en) | Synergistic combination of an alpha-2-delta ligand and a pdev inhibitor for use in the treatment of pain | |
US9907795B2 (en) | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents | |
US20080188497A1 (en) | Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions | |
WO2006069806A1 (en) | Pharmaceutical composition comprinsing a 2,5-dihydroxybenzenesulfonic compounds, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor | |
US20170326140A1 (en) | Novel uses | |
JP2006527257A (en) | Therapeutic combination comprising a PDE inhibitor and a vasopressin receptor antagonist for the treatment of dysmenorrhea | |
KR20050004195A (en) | Novel Combination | |
JP2005531627A (en) | New mixed medicine | |
EA007952B1 (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
US20040132731A1 (en) | Novel combination | |
WO2005042022A2 (en) | Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist | |
US20040077624A1 (en) | Novel combination | |
JP2004520279A (en) | Treatment of premature ejaculation | |
CN101340946A (en) | Pharmaceutical combination for the treatment of luts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |